218 related articles for article (PubMed ID: 15608425)
61. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
62. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M; Kumai T; Hayashi R; Yamaki H; Komatsuda H; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Kobayashi H; Harabuchi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3421-3434. PubMed ID: 33866408
[TBL] [Abstract][Full Text] [Related]
63. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract][Full Text] [Related]
64. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
Ferris RL
ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
[TBL] [Abstract][Full Text] [Related]
65. Impact of p53-based immunization on primary chemically-induced tumors.
Cicinnati VR; Dworacki G; Albers A; Beckebaum S; Tüting T; Kaczmarek E; DeLeo AB
Int J Cancer; 2005 Mar; 113(6):961-70. PubMed ID: 15514940
[TBL] [Abstract][Full Text] [Related]
66. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
Theobald M; Ruppert T; Kuckelkorn U; Hernandez J; Häussler A; Ferreira EA; Liewer U; Biggs J; Levine AJ; Huber C; Koszinowski UH; Kloetzel PM; Sherman LA
J Exp Med; 1998 Sep; 188(6):1017-28. PubMed ID: 9743520
[TBL] [Abstract][Full Text] [Related]
67. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
Svane IM; Pedersen AE; Johnsen HE; Nielsen D; Kamby C; Gaarsdal E; Nikolajsen K; Buus S; Claesson MH
Cancer Immunol Immunother; 2004 Jul; 53(7):633-41. PubMed ID: 14985857
[TBL] [Abstract][Full Text] [Related]
68. Immune alterations and immunotherapy prospects in head and neck cancer.
Varilla V; Atienza J; Dasanu CA
Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
[TBL] [Abstract][Full Text] [Related]
69. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
Voskens CJ; Sewell D; Hertzano R; DeSanto J; Rollins S; Lee M; Taylor R; Wolf J; Suntharalingam M; Gastman B; Papadimitriou JC; Lu C; Tan M; Morales R; Cullen K; Celis E; Mann D; Strome SE
Head Neck; 2012 Dec; 34(12):1734-46. PubMed ID: 22287423
[TBL] [Abstract][Full Text] [Related]
70. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.
Schmitt A; Barth TF; Beyer E; Borchert F; Rojewski M; Chen J; Guillaume P; Gronau S; Greiner J; Möller P; Riechelmann H; Schmitt M
Int J Oncol; 2009 Mar; 34(3):629-39. PubMed ID: 19212667
[TBL] [Abstract][Full Text] [Related]
71. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.
Andrade Filho PA; López-Albaitero A; Gooding W; Ferris RL
J Immunother; 2010 Jan; 33(1):83-91. PubMed ID: 19952953
[TBL] [Abstract][Full Text] [Related]
72. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
[TBL] [Abstract][Full Text] [Related]
73. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.
Chai SJ; Fong SCY; Gan CP; Pua KC; Lim PVH; Lau SH; Zain RB; Abraham T; Ismail SM; Abdul Rahman ZA; Ponniah S; Patel V; Cheong SC; Lim KP
Hum Vaccin Immunother; 2019; 15(1):167-178. PubMed ID: 30193086
[TBL] [Abstract][Full Text] [Related]
74. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
[TBL] [Abstract][Full Text] [Related]
75. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.
Petersen TR; Bregenholta S; Pedersen LO; Nissen MH; Claesson MH
Cancer Lett; 1999 Apr; 137(2):183-91. PubMed ID: 10374840
[TBL] [Abstract][Full Text] [Related]
76. Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma.
Shibuya TY; Wei WZ; Zormeier M; Ensley J; Sakr W; Mathog RH; Meleca RJ; Yoo GH; June CH; Levine BL; Lum LG
Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):473-9. PubMed ID: 10772300
[TBL] [Abstract][Full Text] [Related]
77. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors.
Röpke M; Regner M; Claesson MH
Scand J Immunol; 1995 Jul; 42(1):98-103. PubMed ID: 7543215
[TBL] [Abstract][Full Text] [Related]
78. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
Song GY; Gibson G; Haq W; Huang EC; Srivasta T; Hollstein M; Daftarian P; Wang Z; Diamond D; Ellenhorn JD
Cancer Immunol Immunother; 2007 Aug; 56(8):1193-205. PubMed ID: 17219151
[TBL] [Abstract][Full Text] [Related]
79. BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.
Sánchez-Rodríguez C; Cruces KP; Riestra Ayora J; Martín-Sanz E; Sanz-Fernández R
Vaccine; 2017 Nov; 35(47):6395-6403. PubMed ID: 29029943
[TBL] [Abstract][Full Text] [Related]
80. Identification of an HLA-A2-restricted CD147 epitope that can induce specific CTL cytotoxicity against drug resistant MCF-7/Adr cells.
Qu C; Gao S; Shao H; Zhang W; Bo H; Lu X; Chen T; Kou J; Wang Y; Chen GS; Huang S; Shen H
Oncol Lett; 2018 Apr; 15(4):6050-6056. PubMed ID: 29556319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
